Black Creek Investment Management Inc. Cuts Position in Grifols, S.A. $GRFS

Black Creek Investment Management Inc. reduced its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 1.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,569,638 shares of the biotechnology company’s stock after selling 121,249 shares during the quarter. Grifols makes up approximately 5.3% of Black Creek Investment Management Inc.’s holdings, making the stock its 8th biggest position. Black Creek Investment Management Inc. owned approximately 1.83% of Grifols worth $113,630,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GRFS. Vestmark Advisory Solutions Inc. acquired a new stake in Grifols in the 2nd quarter valued at $414,000. Campbell & CO Investment Adviser LLC increased its position in shares of Grifols by 516.4% in the second quarter. Campbell & CO Investment Adviser LLC now owns 109,464 shares of the biotechnology company’s stock valued at $990,000 after acquiring an additional 91,706 shares during the last quarter. Advisors Preferred LLC bought a new stake in Grifols during the first quarter worth about $368,000. Vident Advisory LLC boosted its position in Grifols by 134.5% during the first quarter. Vident Advisory LLC now owns 69,564 shares of the biotechnology company’s stock valued at $495,000 after purchasing an additional 39,902 shares during the last quarter. Finally, Groupe la Francaise bought a new position in Grifols in the first quarter valued at approximately $1,699,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Grifols in a research report on Tuesday, August 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Grifols in a research report on Wednesday, October 8th. Finally, Zacks Research lowered shares of Grifols from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.30.

Grifols Price Performance

Shares of Grifols stock opened at $8.50 on Tuesday. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $5.84 billion, a price-to-earnings ratio of 44.74, a price-to-earnings-growth ratio of 0.32 and a beta of 0.69. Grifols, S.A. has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a 50-day simple moving average of $9.46 and a two-hundred day simple moving average of $9.31.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.